Christophe Weber, Takeda CEO (Kosuke Okahara/Bloomberg via Getty Images)
July 31, 2024 01:21 PM EDT
R&D
Pharma

Take­da de­fends Alzheimer's pact, TYK2 po­ten­tial as re­struc­tur­ing is in 'full swing'

Kyle LaHucik

Senior Reporter

In its quar­ter­ly up­date on Wednes­day, Take­da ex­ec­u­tives said the Japan-based phar­ma gi­ant’s $900 mil­lion re­struc­tur­ing is in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times